Milrinon Devrimed (Milrinone)

• Milrinone acts as an inotropic and vasodilator agent for severe cardiac conditions.
• Acute decompensated heart failure: improves cardiac output and reduces systemic vascular resistance.
• Cardiogenic shock: provides essential inotropic support to maintain organ perfusion.
• Post‑cardiac surgery low cardiac output: assists in stabilising hemodynamics after major cardiac procedures.

• Milrinone selectively inhibits phosphodiesterase‑3 enzymes in cardiac and vascular smooth muscle cells, leading to increased intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while also promoting vasodilation through reduced calcium‑mediated smooth‑muscle contraction, thereby lowering afterload.

Milrinone may be associated with a range of adverse reactions that clinicians monitor during therapy.

Common Side Effects

• Hypotension: drop in blood pressure, especially with rapid infusion.
• Arrhythmias: premature ventricular contractions or tachyarrhythmias.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.
• Flushing: warmth and redness of skin.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Severe hypotension: profound blood pressure fall requiring intervention.
• Ventricular tachycardia or fibrillation: life‑threatening rhythm disturbances.
• Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
• Thrombocytopenia: notable drop in platelet count.
• Hepatic enzyme elevation: increased ALT/AST levels.
• Allergic reactions: rash, urticaria, or anaphylaxis.

• Milrinone therapy requires careful patient assessment and monitoring.
• Cardiovascular monitoring: continuous ECG and blood pressure observation.
• Electrolyte balance: correct potassium and magnesium before initiation.
• Renal function: adjust infusion in patients with impaired clearance.
• Concomitant vasodilators: use cautiously to avoid excessive hypotension.
• Severe aortic stenosis: contraindicated due to risk of outflow obstruction.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Milrinone can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

• Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.
• Nitrates: risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt inotropic response.
• Calcium channel blockers: potential for enhanced vasodilation.
• Diuretics: electrolyte shifts may predispose to arrhythmias.
• Digoxin: monitor for synergistic effects on cardiac rhythm.